Chemed raises 2024 EPS outlook to $23.55-$23.80 after 34% Q2 adjusted EPS gain
Chemed reported second-quarter 2024 revenue of $595.9 million, up 7.6%, and GAAP diluted EPS of $4.65, up 32.5%. The company raised its full-year 2024 adjusted EPS estimate to $23.55-$23.80 from the prior $23.30-$23.70, a higher outlook for shareholders.
- Q2 2024 revenue rose 7.6% to $595.9 million; adjusted diluted EPS was $5.47, up 34.1%
- VITAS revenue rose 16.7% to $374.6 million, while Roto-Rooter revenue fell 5.0% to $221.3 million
- 2024 adjusted EPS guidance raised to $23.55-$23.80 from $23.30-$23.70
- As of June 30, 2024, cash and cash equivalents were $222.9 million with no current or long-term debt